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The success reported for the treatment of superficial 
skin carcinomas by photodynamic therapy with top-
ical application of the photosensitizer precursor 
5-aminolevulinic acid has therapeutic implications 
for the treatment of other sldn disorders. This paper 
describes the accumulation of the photosensitizing 
agent protoporphyrin IX in areas of plaque psoriasis 
by monitoring of the fluorescence emission induced 
by low-intensity laser excitation at 488 nm. We 
present results from 15 patients with a total of 42 
plaques and show that the characteristic fluorescence 
emission of protoporphyrin IX increases in intensity 
within the 6-h period following application of 5-ami-
nolevulinic acid. suggesting that there is a potential 
S Ln ce Kennedy ef al (1990) first described the treatment of superficial skin carcinomas by photodynamic therapy (PDT), usiJlg topica l app li ca tion of the photosensiti zer precursor 5-aminolevulinic acid (ALA), other cente rs (Wolf ef ai, 1993; Ca irndufF ef ai, 1994; Svanbel'g ef ai, 
1994; Fij~1I1 ef ai , 1995) have reported the e fFectiveness of this type 
of treatment. The perceived advantages of ALA-PDT, notably the 
localized and short-tcrm photosensitivity, have led to consideration 
of the teclmique for other sites of malignan cy or premalignan cy 
su ch as Barrett's esophagus · (Barr ef ai , 1995) and for nonmalignant 
conditio ns that involve on ly the most superficia l tissue layer, such 
as the endometrial surface of the uterus (Gannon el ai , 1995). 
T he use of photodynamic therapy to treat psoriasis was first 
reported in 1937; usin g systemic administration of hematoporph y-
rin in combinatio n with ultraviolet rad iation, Si lver reported im-
provement in seven patients (Si lver, 1937). Subsequent workers 
have a lso reported the efficacy of hemato porphyrins administered 
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for superficial photodynamic therapy. The rate of 
increase and maximum intensity of fluorescence 
emission was not directly related to the applied quan-
tity of the precursor. The variability of the fluores-
cence intensity was as great between plaques at dif-
ferent sites on the same patient as between different 
patients. Also. the effect of plaque occlusion follow-
ing application appeared insignificant. Although 
there was only limited enhancement of emission from 
areas of sldn surrounding the plaque. a significant 
build-up of sensitizer was detected after several days 
in some areas of psoriasis that received no applica-
tion. Key words: jlllOl'eSCellcelpilOtosellsitiz atiOll, J I,west 
Demratol 107:76-81, 1996 
systemically followe d by 630-nm ilJumination (Berns el ai, 1984) or 
topica lly using ultraviolet or visible radiation (MefFert el ai, 1989). 
The resu ltant prolonged photosensitivity was recogni zed as the 
major limi tation of system ic administration for thi s form of treat-
ment. Recently, Boehncke ef al (1994a) reported th e decrease in 
Auorescen ce emission (photobleachin g) of the photosensitizer Pho-
tosal1-3 induced by illumination at 630 nm after topical appUcation 
to psoriatic plaques . The same author (1994b) h as subsequ ently 
de monstrated the possibility of topica l ALA-PDT in therapy by 
achieving clearance comparabl e to that with dithranol in chronic 
plaque-stage psoriasis in three patients. It had pre viously been 
observed (Kenn edy and Pottie r, 1992) th 'lt top ica l ALA-induced 
protoporphyrin IX (PpIX) was confined to areas of psoriasis , but 
the clinica l response to illumination was variable. 
In order to max; mize PDT e ffe ctiveness afte r application of ALA, 
illumination of the treatment area sh ou ld occur at a time of 
sufficiently increased concentration of the endogeno us photosensi-
tizer. The accumu lation of intracellular PpIX is governed b y the 
heme biosynthetic pathway and is therefore dependent upon the 
d iffusion rate of exogenous ALA throughout the abnormal epithe-
liUln and by the rate of h em e formation. it has been shown (Loh eI 
ai , 1993) that difFerent types of tissue m etabolize the sensitizer at 
difFerent rates and to difFe rent degrees. In the treatment of super-
ficia l skin carcinomas reported to date, time inte rval s of 3 to 20 h 
have been adopted between ALA application andilJumination . 
With ALA in com bimltion with the iron chelator desferrioxamine, 
favorab le results were reported (Fijan cl ai , 1995), particularly for 
thicker les ions such as nodular basal cell carcinomas that were 
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ascribed to the inhibi tion of heme formation and a concomitant 
enhancement of PplX concentration . 
T he purpose of our study was to (i) monito r the rate of 
accumulation and persistence of PpIX in plaque psoriasis; (ii) 
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Figure 1. T h e extraction of photo-
sensitizer fluorescence fronl the 
autofluorescence background. The 
shape of the autofluorescence curve 
was recorded upon areas of plaque not 
app lied with ALA. enabling a back-
ground sub traction that yields the emis-
sion d ue to Pp IX. T he he igh t of the 
635-nm peak is plotted against time 
after app lication. to indicate the 
progress of Pp lX synthes is. 
determine the effect of different quantities of applied ALA upon the 
rate and level of PpiX accul11ulation; (iii ) determin e the effect of 
occlusion of the plaque, followi ng ALA appli cation , upon the rate 
and level of PpIX accumulation ; (iv) investigate the degree of 
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F igure 2. PpIX fluorescence intensity vers"s time after ALA application. M easurements were made on a pati en t (group 1) with fo ur areas of elbow 
plaque psoriasis using 50 . 100. and 200 mg of A L A (20'X.) in Unguen tul11 Merck within 2 X 2 cm test sites. 
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Figure 3. Time plots of PpIX fluorescence intensity, using the 
three different quantities of ALA preparation. !<'esults arc presented 
from 5 of the 10 patients in group 1, with each symbol representativc of an 
individual patient. T hese graphs include the data points that exhibitcd the 
greatest extremes of fluorescence intensity. 
localization ofPpIX to the area of ALA application. T he resul ts are 
used to assess the potential for superficial PDT and establish 
appropriate treatment conditions. 
MATERIALS AND METH ODS 
Experimental Apparatus Fluorcsccncc was induccd with the 488-nm 
o utput from an argon- ion lascr deli vc red to the surf.,ce of the skin via a 
600-JLm-core optical fi bcr at a power of4 mW. A second fiber was used to 
collcct the cmitted light, which was fi ltered (OG 530, long-pass) to block 
the sca ttered lascr radi ation and dcli vered to thc entrance slit of a 
singlc-channc l optica l spectrum analyzcr (Rces Instruments Ltd, Goda lm-
ing, UK). T hc delivcry and detector fibcrs arc arranged normal to thc skin 
surface in a hand-held probe that analyzes a circu lar area of 0.1 cm 2 , 
resulting in a locali zed irradi ance of 40 m W cm - 2 • The spectrum ana lyzcr 
cmploys a rcvolving diffraction grating to capture a completc spectrum 
(450-900 nm) every 80 ms. w hjch is regi stered by a red-scnsitive photo-
multipljer tu be . T lus ensu rcs d,at nonlinearity of dctector responsc is 
avo ided, bu t in o rde r fo r an adeq uate signal-to-noise ratio to be achjeved, 
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Figure 4. Time plots ofPpIX fluorescence intensity from occluded 
and nOlloccluded sites . Resul ts wcre obtained from 5 patients (group 2) 
using 50 m g cm - 2 of ALA prepa ration . Error /Ja rs , m ean ± SO of three 
measurements fro m closely sp"ccd points w ithin the same pl"q ll c. 
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F igure 5. The intensity ofPpIX fluorescence across an area of plaque and the border ofnonnal skin. T he m easurem ents were m ade 4.3 h after 
ALA app lication (50 mg cm - 2) upo n a patient in group 1. 
sequential spectra must be averaged. Each spectrum presented here w.:~ 
collected over a period of 20 s. T hi s resu lts in a li ght dose of 0.8 J Clll -
del.ive red to the area of anal ys is during every measurem ent. 
Patients T hese stud ies were approved by the ethi ca l commi ttee of the 
h ospital. Consecutive patients w ith chro nic plaque pso ri asis were n!cruited , 
and each gave w ri tten info rmed consen t. All had been trea ted previously 
with topica l the rap)' (tar, dithranol , or calcipotrio l). often in combmaoon 
with UV13 phototherapy. N one was undergoing treatm ent at the time of 
recrui tment o r had rece ived phototherapy during 4 m o nths prior to the 
study. EmoU.ient (aqueous cream) o nl y was used fo r 2 weeks before topical 
ALA. 
In 10 pa tie nts (group '1) , e ithe r three o r fo ur sq uares (2 X 2 cm) were 
defined o n each that were within o r overl apping an area of psoriasis. A tota l 
of 32 sites were studied, of w hich 5 were biopsied. T he plaques were 
located upon the elbows (4 patients). forearm (4), back (l), and thigh (1). 
No formal assess men t was m ade of plaque thickness. ALA (Sigma C hemica l 
Co. Ltd , UK), dissolved (20'1., by w eight) in a proprieta ry o il-in-water 
e mulsion (Unguentul11 M erck. W hi tehall Laboratories Ltd, UK). w~s 
ap plied to the chosen sites in qua ntities <:~ 50, 100. or 200 m? fo r 1 h. T IllS 
corresponds to 12.5, 25, and 50 m g cm - o f cream. respective ly. FluOl'es-
cence spectra were recorded fi,o lll these sites at ti me po ints between 83 and 
360 min. In four of the pa tients. flu orescence spectra were taken after 4 d. 
Tn twO patie nts m easurem ents we re made (at around 4 h) tra n svers~ l y :,cross 
the plaque and beyond in o rder to determine the degree of locahzaoon of 
the accumula ted pplX to the arca of application . . 
Five pati e nts w ith symmetrical plaq ue pso ria sis at the e lbows (group 2) 
had a test site (2 X 2 cm) defined w ithin each plaque . ALA 20% in 
U n guel1tum Merck was app lied at a quantity of 50 mg cm - 2 to both squares. 
One was then covered with a transparent po lythene dressing (Tegaderm , 
3M Health Care Ltd, Loughbol"Ough , UK) to form an occluded site and 
residual ALA was removed fi'o lll the non occluded site afte r '1 h. Fluores-
cence meas urernents were made from 80 to 360 mi.ll after application ; on 
the occluded sites the m easurem ents were made thro ugh the po lythene . 
Data Analysis Figure 1 illustrates the procedure involved in obtaini~~ 
the photosensitizer fluorescence spectrum . In thi s example. 12.5 m g cm -
of the ALA preparation was app lied to a plaque upon the elbow. The 
fluorescence speco'a were recorded at times ranging from 85 to 280 min 
after app li ca tion and then aga.in afte r 4 d . It is clear fro m the spectra shown 
that the tissue autofluorescence dominated the recorded signal. Also. 
although the experimen tal pa ram eters rem ained constant for all m easure-
l11 cncs. there \vas considerable variation in the intensity of autofluorescence, 
even for repeated measurements upon the sam e plaque , but b y anal ysis of 
the shape of an "veraged autofl uorescence spectrum (obta ined from mea-
surem ent points upon at leas t one area of plaque not exposed to ALA, on 
each patient), a background correction could be m ade to a \J ow the 
subtractio n of the autofluorescence o utpu t fro m the tota l. T illS yielded the 
photosensitizer fluorescence spectrum . T he inrcnsity of the 488-nm excita-
tion was recorded prio r to each measuremen t and va l;cd by up to :!: 5% 
from the m ean . T he spectra were therefore normali zed for laser power 
va riatio ns after the backgro und correction. 
A plot of the heigh t of the 635-1U11 emission peak as a function of timc 
afte r application demonstrated the b uild- up of PpIX w ithin the area of 
analysis. T he error bars represen t thc standard deviation of three readings 
taken fro l1l close ly spaced points within the same plaque. T he major 
con tribu tion to the crror is a resul t of subtraction of thc autofluorescent 
background. A second m easurem e nt at the sam e point. performed imme-
diately after the first. ind icates that the peak fluorescence intensity of PpIX 
is reduced by approximately 5%, a cOlISequcnce of SClISitizer photo-oxidation 
during the period of measurement. None of the data presented here. however. 
involved such a repetition. and we have not. therefore. attempted to apply a 
photobleaching cOITection to individual m easurements. 
RESULTS 
Evidence of PpIX Accumulation T h e Auorescen c~ in.tensity 
from ALA-induced PplX in creased with time after appbcabon for 
all patients studied. Figure 2 shows the compl ete set of results from 
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F igure 6. PpIX fluorescence spectra recorded at time points up to 4 h , and then after 4 d. M easurem ents were made at p laque sites upon the elbow 
that had rece ived ALA, as well as untreated sites of adjacent and remote plaq ues and no rmal skin . 
the four areas of investigation upon the pati ent from which Fig 1 
w as derived. T here was a steady in crease in emi ssio n intensiry 
between 1 and 5 h and the re w as evidence of the presence of PpiX 
4 d after the initial m easurem ents. After a further 3 d no signal 
persisted . A comparison of the Auorescence m easured within an 
area of plaque and that upon its bo rder illustrates the low level of 
photosensitizer production in the adj acent skin . 
The Effect of Using Different Quantities of ALA Is Not 
Significant Figure 3 shows the results from 5 of the 10 patients 
upon which the three different quantities of ALA were applied. 
T hese graphs include the data points from patients that exhibited 
the grea test extremes of Auorescence in tensiry. T he plots that are 
omitted (fo r clariry) ail lie within these extrem es. For each concen-
tratio n of ALA used there was a signifi cant increase in PpIX 
Auorescence, but the intensity of Auoresccnce obtained with o nly 
50 m g of ALA preparatio n was mu ch more variable between 
patients than that induced by th e use of 100 or 200 m g. 
The Effect of Plaque Occlusion Is Not Significant The 
effect upon the ALA-ind uced PplX accumulation of plaque occlu-
sion by applica ti on of a polythene dressing' is shown in Fig 4 . Only 
in one patient did there appear to be ev idence of a signifi cant 
difference in Auorescence intensity between occluded and non oc-
cluded si tes over the whole period of analysis. 
Enhanced PpIX Accumulation in Plaque, Compared to 
Adjacent Skin Figure 5 sho ws the results of m easurem ents 
made transversely across an area of skin that contained a small 
plaque 4.3 h after application of cream. The intensity of th e 635-nm 
peak is shown to be almost equal across the p laque, with a much 
lower « 25%) emission from the skin m argin tha t had received 
ALA. Away £i'om the area of application, the signal was reduced to 
less than 5% of the maximum . 
Evidence ofPpIX in Untreated Plaque The spectra shown in 
Fig 6 are derived from a patient in group 1. M easure ments were 
made upon sites that included p laque treated w ith ALA, adjacent 
nontreated plaque, remote plaque, and areas of normal skin. These 
spectra show that over the first few hours, only those sites receiving 
ALA displayed a PpIX emjssion. After 4 d, however, not only had 
the Auorescence intensiry doubled at the sites of application, but 
there was also a significant emission in non treated points on the 
same p laque as w ell as in a plaque separated (> 15 cm) from those 
treated. The signal obtained from normal skin was smaller than the 
trea ted plaques by at leas t a factor of 1 00 , and 50 times smaller than 
that in the remote plaque . 
DISCUSSION 
It sho uld be emphasized that these are m acroscopic measurements 
that register the average Auorophor distribution within the 0.1 -cm 2 
area of ana lysis . T he microscopic distribution of photosensitizer and 
tissue Auorescence is not resolved by tllis tedl.llique. The use of 
488-nm excitation limits the analysis to the epidermis, and so w e 
can conclude from these m easurem ents that the synthesis of PplX 
proceeds effectively in p laqu e psoriasis after topical application of 
ALA. In all examples, the re was a steady bui ld- up in Auorescence 
intensity during the fust 4 h , with instances of continued PpIX 
accumulation up to 5 h and beyond . There were considerable 
variations in bo th the rate of increase and the maximum intensity of 
Auorescence achieved . These variations were as great between 
differen t si tes on the same patient as between different patients . T he 
PpIX accumulation was not significantly dependent upon the 
applied quantity of ALA, although in the sample studied (gro up 1) 
the smallest variation in data points was obtained with a concen-
tratio n of 25 mg cm - 2 , When the patient and site variations are 
taken into account, the effect of occluding the p laque fo llowing 
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ALA application also appears not to be significant, implying that 
occlusion does not enhance ALA penetration . Such variations also 
preclude any accurate prediction of PpIX accumulation at different 
sites upon the body, although the data from this study do suggest 
that the m ost intense fluorescence is o btained from plaques located 
upon the elbows. T he five biopsy sa mples are currently undergoing 
analysis by fluores cence microscopy in order to establish the 
epidermal distribution of PpIX. 
T h ere was a m easu rable PpIX content in th e border of skin 
immediately adjacent to a plaque when both received ALA. Skin 
not covered by cream showed a much less sig nifi cant enhancem ent. 
It is likely that the proximity of the po int of m easurem ent to the 
plaque is the dominant factor in this e fFect. 
Results o btained fi:om one patient show not only that those 
plaques treated with ALA display an enhanced PpIX content after 
severa l days , but also that remote plaques display significant 
fluorescence. Although the m agnitude of effect in this individual is 
the greatest that has been m easured to date, the persistence and 
distribution of the fluorescence has been registered in other patients 
and raises some important ques tions regarding this type of drug 
application . The separatio n of the sites involved and the supervisio n 
of the patient over the initial period after application (during which 
most if not all of the ALA is absorbed) indicates that the ALA is not 
tran sferred to the remote sites by direct contact, which implies a 
biochemical transport mechanism either for the photosensitizer or 
the precursor. T he bloodstream is the m ost o bv ious candidate for 
sys temic distribution of either of these agents; a program of blood 
sampling over an extended time period afte r application of ALA IS 
now in progress. 
T he intensity of fluorescen ce emission reported in tlus study is 
comparable to, and in man y cases greater than , m easurem ents we 
have m ade upon areas of superficial skin carcinoma. This indicates 
that PDT has the potential to be a beneficia l therapy for plaque 
psoriasis. Using these findings, we have established a treatment 
protocol that involves using 100 mg of 20')1" ALA in Unguentum 
Merck with no occl usion of the site and with the subsequent PDT 
illumination to proceed at a time point of 3 .5 h after application. 
Lack of occlusion allows the possibility of unsupervised application 
of the crea m by th e patient several hours before attending the 
clinic. A clini cal trial is underway, involving the superficia l illumi-
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nation of selected areas of plaque psoriasis using a broad-spectrum 
light source . 
vVe Iltallk lite Dept/rllll elll 0f Pllarlllaey, Leeds General bifirlllat)',forpreparalioll of 
lit e ALA, alld !/Ie appreciate lite co-operalioll alld patiellee 'if Ihose lakillg 1'(//1 ill Ihis 
slIIdy. TI,is !/Iork !/las slIpporled by jillldillg fimll tlte Yorksltire Calleer R esearclt 
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